Patent applications published 20 April 2011

Published: 31-May-2011
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Method of treating traumatic brain injury
    Oxygen Biotherapeutics 2309849*

  • Surface-immobilised antimicrobial peptoids
    Northwestern University 2309850*

  • Antimicrobial polymers and their use
    DSM IP 2309851*

  • Novel method
    GlaxoSmithKline 2309852*

  • Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
    Lixte Biotechnology; The United States of America, as represented by the Secretary of Health and Human Services 2309853*

  • Accelerated therapy
    Gloucester Pharmaceuticals 2309854*

  • Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same
    Oncotherapy Science 2309855*

  • Pharmaceutical compounds as cytotoxic agents and the use thereof
    Myrexis 2309856*

  • Compsns and methods for treating inflammatory disorders
    Dekel Pharmaceuticals 2309858*

  • Enzyme inhibitors and the use thereof
    Dara Biosciences 2309859*

  • Monocyclic cyanoenones and methods of use thereof
    Trustees of Dartmouth College 2309860*

  • Isoamyl acetate for weight management
    Nestec 2309877*

  • Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic
    Merck Patent 2309974*

  • Bitablets comprising compacted polyallylamine polymer and method for the production thereof
    Ratiopharm 2309977*

  • Dry powder pharmaceutical compsns for pulmonary administration, and methods of manufacturing thereof
    3M Innovative Properties Company 2309978*

  • Delivery of dry formulations of octreotide
    Endo Pharmaceuticals Solutions 2309979*

  • Ophthalmic compsns for treating pathologies of the posterior segment of the eye
    S.I.F.I. Societa’ Industria Farmaceutica Italiana 2309980*

  • Dermatological compsn that can be used in particular for the care and prevention of eschars
    Laboratoires Carilene 2309981*

  • Controlled release copolymer formulation with improved release kinetics
    Tolmar Therapeutics 2309982*

  • Pharmaceutical form comprising tetrahydrobiopterin
    Orpha Swiss 2309983*

  • Method of making a dry powder pharmaceutical compsn
    3M Innovative Properties Company 2309984*

  • Pharmaceutical compsn
    Takeda Pharmaceutical Company 2309985*

  • Melt granulation process
    Novartis 2309987*

  • High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
    Albemarle Corp 2309988*

  • Drug loaded polymeric nanoparticles and methods of making and using the same
    Bind Biosciences 2309989*

  • Drug loaded polymeric nanoparticles and methods of making and using the same
    Bind Biosciences 2309990*

  • Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using the same
    Bind Biosciences 2309991*

  • Pharmaceutical compsn comprising a statin
    Krka Torvarna Zdravid D D Novo Mesto 2309992*

  • Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
    US Worldmeds 2309993*

  • Sustained release pharmaceutical compsns comprising quetiapine
    Lupin 2309994*

  • Pharmaceutical formulation for lowering pulmonary blood pressure
    Ratiopharm 2309995*

  • Amorphous ambrisentan
    Ratiopharm 2309996*

  • Compsn and method of preparation of release systems for constant (zero-order) release of active agents
    Appian Labs 2309997*

  • Effervescent tablets/granules
    Phyzz 2309998*

  • Coated particles containing pharmaceutically active agents
    McNeil-PPC 2309999*

  • Dermal delivery
    Anterios 2310000*

  • Transdermal estrogen device and delivery
    Noven Pharmaceuticals 2310001*

  • Protective gel based on chitosan and oxidised polysaccharide
    Medtronic 2310002*

  • Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
    Meta-IQ 2310003*

  • Niacin compsns for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer’s diseases (AD)
    Kareus Therapeutics 2310004*

  • Treatment of inflammatory conditions with isothiocyanates
    Provexis Natural Products; Plant Bioscience 2310005*

  • Treating cancer
    Mayo Foundation for Medical Education and Research 2310006*

  • Improving renal function with quercertin-containing compsns
    Quercegen Pharmaceuticals 2310007*

  • pH-specific solutions of sodium mycophenolic acid for the treatment of eye disorders
    Aspreva International 2310008*

  • Parenteral and oral formulations of benzimidazoles
    University of Houston 2310009*

  • Chemical compounds 251
    AstraZeneca 2310010*
See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now